Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATE

EJNMMI Physics

Table 1 Summary of patient characteristics and personalized [¹⁷⁷Lu]Lu-DOTATATE therapy (n = 6)

Patient	Age at first treatment cycle (years)	Sex	GFR (mL min⁻¹)	Baseline weight prior to each cycle (kg)	Per cycle administered amount of radioactivity (GBq)	Per cycle administered amount of radioactivity per weight (MBq/kg)
P1	10	F	144	37.2, 42.8, 42.8, 44.0	2.86, 3.67, 4.68, 4.25	76.9, 85.7, 109.3, 96.6
P2	6	M	77	19.0, 22.6, 23.6, 25.4	1.45, 2.16, 2.57, 2.86	76.3, 95.6, 109, 113
P3	5	M	115	21.4, 24.2, 25.8, 27.1	1.54, 2.00, 2.07, 2.15	71.9, 82.6, 80.2, 79.3
P4	10	F	122	33.0, 35.7, 37.2, 38.2	2.55, 3.61, 3.54, 3.60	77.2, 101, 95.2, 94.2
P5	4	M	83	20.0, 19.6, 21.0, 21.8	1.55, 2.08, 2.04, 2.39	77.5, 106, 97.1, 110
P6	11	F	122	34.5, 39.5, 42.9, 46.1	3.05, 4.11, 3.70, 4.71	88.4, 104, 86.2, 102